John Carroll, Founder of Endpoints News and Inventor of FierceBiotech, shared a post on X:
“Outstanding piece here from Lei Lei Wu on AstraZeneca‘s in vivo CAR-T for multiple myeloma. There’s data on 5 patients, which is pretty lean, but 4 come out MRD negative in two months, which is extraordinary. We’re going to see a lot more of these cancer studies looking at minimal residual disease, and researchers are likely paying close attention.
There is a question on safety, as there often is with extremely sick patients and CAR-T. But very promising for the closely watched in vivo space. And all laid out in crystal clear language. Two thumbs up, Lei Lei.”
Other articles about Multiple Myeloma on OncoDaily.